Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.39 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22646175 | 1.00 | DNM1 (0.46) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL277799 | 0.97 | LMNA (0.42) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL9818090 | 0.97 | LMNA (0.42) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL13851797 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL5692575 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL1678737 | 0.92 | DNM1 (0.46) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL12479364 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL11681882 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL11701212 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 | |
| SCHEMBL20054095 | 0.92 | TSHR (0.47) | DNM1LMNATSHRTHRBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524943-B1 | Benzocarbonyl compounds | YAP1, TEAD2, TEAD3 | DNM1 286/4885LMNA 1755/4885TSHR 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.